Arecor Therapeutics (LON:AREC) Trading Down 3.9% – Here’s Why

Arecor Therapeutics plc (LON:AREC) shares traded down 3.9% on Thursday . The company traded as low as GBX 61 and last traded at GBX 61. Approximately 45,533 shares were traded during trading, an increase of 122% from the average daily volume of 20,513 shares. The stock had previously closed at GBX 63.50.

Arecor Therapeutics Stock Down 2.5%

The stock has a market cap of £23.01 million, a P/E ratio of 30.48 and a beta of -0.18. The stock’s 50-day moving average is GBX 66.37 and its 200-day moving average is GBX 73.21. The company has a current ratio of 4.35, a quick ratio of 6.24 and a debt-to-equity ratio of 1.52.

Arecor Therapeutics (LON:AREC) last issued its quarterly earnings results on Monday, April 13th. The company reported GBX 2 earnings per share (EPS) for the quarter. The company had revenue of GBX 171 million for the quarter. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%. As a group, research analysts anticipate that Arecor Therapeutics plc will post -0.35 earnings per share for the current fiscal year.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.